• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pulmonary Tuberculosis - Pipeline Review, H2 2012 Product Image

Pulmonary Tuberculosis - Pipeline Review, H2 2012

  • Published: October 2012
  • 59 pages
  • Global Markets Direct

Pulmonary Tuberculosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Pulmonary Tuberculosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Tuberculosis. Pulmonary Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Pulmonary Tuberculosis.
- A review of the Pulmonary Tuberculosis products under development by companies READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Pulmonary Tuberculosis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Pulmonary Tuberculosis 8
Pulmonary Tuberculosis Therapeutics under Development by Companies 10
Pulmonary Tuberculosis Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Pulmonary Tuberculosis Therapeutics – Products under Development by Companies 17
Pulmonary Tuberculosis Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Pulmonary Tuberculosis Therapeutics Development 19
Sequella, Inc. 19
Pulmonary Tuberculosis – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
SQ-109 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SQ-609 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
r30 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
metronidazole - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
rifapentine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
linezolid - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PA-824 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Moxifloxacin + Isoniazid + Rifampicin + Pyrazinamide + Ethambutol - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
cholecalciferol - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PA-824 + Pyrazinamide + Moxifloxacin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SQ109 + Rifampicin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PA-824 + Pyrzinamide - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TMC207 + Pyrazinamide - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Moxifloxacin + Isoniazid + Rifampicin + Pyrazinamide + Ethambutol - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 45
moxifloxacin hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
acetylcysteine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ID93 + GLA-SE Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
pascolizumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Pulmonary Tuberculosis Therapeutics – Drug Profile Updates 51
Pulmonary Tuberculosis Therapeutics – Discontinued Products 53
Pulmonary Tuberculosis Therapeutics - Dormant Products 54
Pulmonary Tuberculosis – Product Development Milestones 55
Featured News & Press Releases 55
Jul 02, 2012: Janssen Submits New Drug Application To FDA For Bedaquiline For Multi-Drug Resistant Tuberculosis Treatment 55
Oct 18, 2010: Sequella Receives International Support For Phase II Clinical Trials Of SQ109 For Treatment Of Adult Pulmonary Tuberculosis 56
Oct 18, 2005: The Global Alliance for TB Drug Development Announces Phase II Trials To Study Potential Of Moxifloxacin To Shorten TB Treatment Partners Commit To Affordable Pricing For Patients In The Developing World 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables
Number of Products Under Development for Pulmonary Tuberculosis, H2 2012 8
Products under Development for Pulmonary Tuberculosis – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Sequella, Inc., H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Pulmonary Tuberculosis Therapeutics – Drug Profile Updates 51
Pulmonary Tuberculosis Therapeutics – Discontinued Products 53
Pulmonary Tuberculosis Therapeutics – Dormant Products 54

List of Figures
Number of Products under Development for Pulmonary Tuberculosis, H2 2012 8
Products under Development for Pulmonary Tuberculosis – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos